Clinical trialsCompany release

XORTX completes clinical supply manufacturing for XORLO oxypurinol gout trial XRX-OXY-102

XORTX Therapeutics Inc. (XRTX) · Mon 16 Nov 2026

XORTX Therapeutics says manufacturing and packaging of drug supply for its oxypurinol tablet gout study is finished, ahead of planned Health Canada and FDA filings.

XORTX Therapeutics announced on 16 November 2026 that it has finished manufacturing and packaging clinical drug supply for XRX-OXY-102, a trial of its oxypurinol tablet XORLO in gout.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): XORTX Therapeutics Inc. ↗

Article written by VigiEye from the official source (XORTX Therapeutics Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →